Hoth Therapeutics (HOTH), a New York-based biopharmaceutical company, announces IP advancements with expanded patent applications for its therapeutic pipeline.
The new patents highlight Hoth's dedication to developing innovative treatments, improving efficacy, and expanding applications for unmet medical needs.
The company invests in research and development to protect and grow its technologies, focusing on advancing its pipeline and delivering impactful healthcare solutions.
HOTH is currently trading at $1.3901 or 7.3267% lower on the Nasdaq Capital Market.
For comments and feedback: editorial@rttnews.com